341 related articles for article (PubMed ID: 24871326)
21. A novel subtype classification and risk of breast cancer by histone modification profiling.
Chen X; Hu H; He L; Yu X; Liu X; Zhong R; Shu M
Breast Cancer Res Treat; 2016 Jun; 157(2):267-279. PubMed ID: 27178334
[TBL] [Abstract][Full Text] [Related]
22. Subtype-specific CpG island shore methylation and mutation patterns in 30 breast cancer cell lines.
Chae H; Lee S; Nephew KP; Kim S
BMC Syst Biol; 2016 Dec; 10(Suppl 4):116. PubMed ID: 28155687
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays.
Rodenhiser DI; Andrews J; Kennette W; Sadikovic B; Mendlowitz A; Tuck AB; Chambers AF
Breast Cancer Res; 2008; 10(4):R62. PubMed ID: 18638373
[TBL] [Abstract][Full Text] [Related]
24. Regulation of estrogen receptor β1 expression in breast cancer by epigenetic modification of the 5' regulatory region.
Al-Nakhle H; Smith L; Bell SM; Burns PA; Cummings M; Hanby AM; Lane S; Parker MD; Hughes TA; Speirs V
Int J Oncol; 2013 Dec; 43(6):2039-45. PubMed ID: 24068253
[TBL] [Abstract][Full Text] [Related]
25. Histone H3 lysine 4 acetylation and methylation dynamics define breast cancer subtypes.
Messier TL; Gordon JA; Boyd JR; Tye CE; Browne G; Stein JL; Lian JB; Stein GS
Oncotarget; 2016 Feb; 7(5):5094-109. PubMed ID: 26783963
[TBL] [Abstract][Full Text] [Related]
26. Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer.
Barrow TM; Barault L; Ellsworth RE; Harris HR; Binder AM; Valente AL; Shriver CD; Michels KB
Int J Cancer; 2015 Aug; 137(3):537-47. PubMed ID: 25560175
[TBL] [Abstract][Full Text] [Related]
27. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
28. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
29. Towards sustained silencing of HER2/neu in cancer by epigenetic editing.
Falahi F; Huisman C; Kazemier HG; van der Vlies P; Kok K; Hospers GA; Rots MG
Mol Cancer Res; 2013 Sep; 11(9):1029-39. PubMed ID: 23814024
[TBL] [Abstract][Full Text] [Related]
30. Methylome and transcriptome analyses reveal insights into the epigenetic basis for the good survival of hypomethylated ER-positive breast cancer subtype.
Chen XQ; Zhang F; Su QC; Zeng C; Xiao FH; Peng Y
Clin Epigenetics; 2020 Jan; 12(1):16. PubMed ID: 31959227
[TBL] [Abstract][Full Text] [Related]
31. Methylation subtypes and large-scale epigenetic alterations in gastric cancer.
Zouridis H; Deng N; Ivanova T; Zhu Y; Wong B; Huang D; Wu YH; Wu Y; Tan IB; Liem N; Gopalakrishnan V; Luo Q; Wu J; Lee M; Yong WP; Goh LK; Teh BT; Rozen S; Tan P
Sci Transl Med; 2012 Oct; 4(156):156ra140. PubMed ID: 23076357
[TBL] [Abstract][Full Text] [Related]
32. DNA methylation and histone modifications in breast cancer.
Dumitrescu RG
Methods Mol Biol; 2012; 863():35-45. PubMed ID: 22359286
[TBL] [Abstract][Full Text] [Related]
33. Hypermethylation in histologically distinct classes of breast cancer.
Bae YK; Brown A; Garrett E; Bornman D; Fackler MJ; Sukumar S; Herman JG; Gabrielson E
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5998-6005. PubMed ID: 15447983
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic and genetic burden measures are associated with tumor characteristics in invasive breast carcinoma.
O'Sullivan DE; Johnson KC; Skinner L; Koestler DC; Christensen BC
Epigenetics; 2016 May; 11(5):344-53. PubMed ID: 27070496
[TBL] [Abstract][Full Text] [Related]
35. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway.
Goeppert B; Konermann C; Schmidt CR; Bogatyrova O; Geiselhart L; Ernst C; Gu L; Becker N; Zucknick M; Mehrabi A; Hafezi M; Klauschen F; Stenzinger A; Warth A; Breuhahn K; Renner M; Weichert W; Schirmacher P; Plass C; Weichenhan D
Hepatology; 2014 Feb; 59(2):544-54. PubMed ID: 24002901
[TBL] [Abstract][Full Text] [Related]
36. Epigenetics of estrogen receptor-negative primary breast cancer.
Huynh KT; Chong KK; Greenberg ES; Hoon DS
Expert Rev Mol Diagn; 2012 May; 12(4):371-82. PubMed ID: 22616702
[TBL] [Abstract][Full Text] [Related]
37. Intratumor heterogeneity index of breast carcinomas based on DNA methylation profiles.
Campoy EM; Branham MT; Mayorga LS; Roqué M
BMC Cancer; 2019 Apr; 19(1):328. PubMed ID: 30953488
[TBL] [Abstract][Full Text] [Related]
38. DNA methylation-dependent epigenetic regulation of gene expression in MCF-7 breast cancer cells.
Rivenbark AG; Jones WD; Risher JD; Coleman WB
Epigenetics; 2006; 1(1):32-44. PubMed ID: 17998816
[TBL] [Abstract][Full Text] [Related]
39. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers.
Chen ST; Lin SY; Yeh KT; Kuo SJ; Chan WL; Chu YP; Chang JG
Int J Mol Med; 2004 Oct; 14(4):577-82. PubMed ID: 15375584
[TBL] [Abstract][Full Text] [Related]
40. Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin.
Lee SE; Kim SJ; Yoon HJ; Yu SY; Yang H; Jeong SI; Hwang SY; Park CS; Park YS
J Pineal Res; 2013 Jan; 54(1):80-8. PubMed ID: 22856590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
